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Background: Galectin-3 is a ß-galactoside-binding lectin expressed in most of tissues in normal conditions and
overexpressed in myocardium from early stages of heart failure (HF). It is an established biomarker associated
with extracellular matrix (ECM) turnover during myocardial remodeling. The aim of this study is to test the ability
of 123I-galectin-3 (IG3) to assess cardiac remodeling in a model of myocardial infarction (MI) using imaging techniques.
Methods: Recombinant galectin-3 was labeled with iodine-123 and in vitro binding assays were conducted to
test 123I-galectin-3 ability to bind to ECM targets. For in vivo studies, a rat model of induced-MI was used. Animals
were subjected to magnetic resonance and micro-SPETC/micro-CT imaging two (2 W-MI) or four (4 W-MI) weeks after
MI. Sham rats were used as controls. Pharmacokinetic, biodistribution, and histological studies were also performed
after intravenous administration of IG3.
Results: In vitro studies revealed that IG3 shows higher binding affinity (measured as counts per minute, cpm)
(p < 0.05) to laminin (2.45 ± 1.67 cpm), fibronectin (4.72 ± 1.95 cpm), and collagen type I (1.88 ± 0.53 cpm) compared to
bovine serum albumin (BSA) (0.88 ± 0.31 cpm). Myocardial quantitative IG3 uptake (%ID/g) was higher (p < 0.01) in the
infarct of 2 W-MI rats (0.15 ± 0.04%) compared to control (0.05 ± 0.03%). IG3 infarct uptake correlates with the extent of
scar (rs = 1, p = 0.017). Total collagen deposition in the infarct (percentage area) was higher (p < 0.0001) at
2 W-MI (24.2 ± 5.1%) and 4 W-MI (30.4 ± 7.5%) compared to control (1.9 ± 1.1%). However, thick collagen
content in the infarct (square micrometer stained) was higher at 4 W-MI (20.5 ± 11.2 μm2) compared to
control (4.7 ± 2.0 μm2, p < 0.001) and 2 W-MI (10.6 ± 5.1 μm2, p < 0.05).
Conclusions: This study shows, although preliminary, enough data to consider IG3 as a potential contrast agent for
imaging of myocardial interstitial changes in rats after MI. Labeling strategies need to be sought to improve in vivo IG3
imaging, and if proven, galectin-3 might be used as an imaging tool for the assessment and treatment of MI patients.
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Myocardial remodeling is one of the principal characteris-
tics of heart failure (HF) [1,2], which remains a major
cause of morbidity and mortality, both in the high and low
income countries [3]. Myocardial remodeling is the result
of alterations in the cellular and subcellular elements of
cardiomyocyte and non-cardiomyocyte components of the* Correspondence: tvarias@cnic.es
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in any medium, provided the original work is pmyocardium and results primarily from the excessive accu-
mulation of collagen in interstitial and perivascular regions
[1]. Initially, the alterations associated with remodeling ap-
pear to compensate for the damage whereas its persistence
over time causes progressive adverse remodeling and re-
sults in HF regardless of the etiology [4]. Given that the
progressive myocardial fibrosis produces abnormalities
that affect cardiac function and electrical activity of the
heart and plays an important role in the development
of HF, it is of great importance to develop novel cir-
culating biomarkers and noninvasive imaging strategies
that accurately define the evolution of myocardial fibro-
sis. In this context, galectin-3 has been proposed as aOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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tion and fibrosis underlying adverse cardiac remodeling
[5-8]. Galectin-3 is a 29- to 35-KDa ß-galactoside-binding
animal lectin [9] expressed by activated macrophages, eo-
sinophils, neutrophils, and mast cells [10]. There are many
ligands for galectin-3, some of them are extracellular matrix
components like laminin or fibronectin [9-11]. Galectin-3
is present in most tissues in normal conditions and overex-
pressed in myocardium from the early stages of HF [12], es-
pecially post-myocardial infarction (MI) [13,14]. Galectin-3
induces myocardial fibroblast proliferation, collagen depos-
ition, and ventricular dysfunction in rats [15]; galectin-3
binding sites are abundantly expressed on rat cardiac fibro-
blasts and within the extracellular matrix (ECM) [15].
Therefore, galectin-3 has been proposed as a biomarker as-
sociated with ECM turnover in the setting of HF [16,17].
The serum levels of galectin-3 in HF patients are signifi-
cantly correlated with other established biomarkers of
ECM turnover such as type III aminoterminal propeptide
of procollagen (PIIINP), matrix metalloprotease-2 (MMP-2),
and tissue inhibitor of metalloprotease-1 (TIMP-1), as
also with the New York Heart Association (NYHA)
functional class [18].
Because binding sites are excessively expressed in ECM
and on proliferating myofibroblasts, we investigated the
suitability of iodine-123-labeled galectin-3 (IG3) as a
single-photon emission computed tomography (SPECT)
probe for myocardial remodeling imaging in a rodent
model of post-MI HF. Animal studies were conducted in
rats 2 and 4 weeks after MI based on our previous studies
with mice [19,20], which demonstrated a peak in fibrosis-
tracer uptake at those time points. Prior to animal studies,
chemical and binding properties of IG3 were tested
in vitro using solid-phase assays.
Methods
Galectin-3 radiolabeling
Galectin-3 radiolabeling was performed using carrier-free
Na123I (Nordion, Ottawa, ON, Canada) and iodotubes
(Pierce, Rockford, IL, USA). Briefly, aliquots of 150 μg
(2 mg/ml) of recombinant human galectin-3 (Peprotech,
Rocky Hill, NJ, USA) were incubated with 1 mCi of Na123I
for 15 min at room temperature (RT). Labeled protein
was separated from free iodine species by gel filtration on
Sephadex G-25 columns (GE Healthcare Bio-Sciences,
Pittsburgh, PA, USA). Afterwards, activity was checked by
gamma counting and protein concentration quantified by
UV spectrophotometry. Radiochemical purity and stability
of the tracer was determined by thin layer chromatog-
raphy (TLC) on silica gel.
Solid-phase radiolabeling binding assay
In vitro solid-phase radiolabeling binding assays were car-
ried out to check whether labeling altered the galectin-3structure and to confirm the ability of IG3 to bind to
ECM targets. Briefly, U-bottom 96-well plates (Becton
Dickinson Labware, Mississauga, ON, Canada), previ-
ously coated with bovine serum albumin (BSA) at 5%,
were incubated (overnight at 4°C) with galectin-3
targets, namely fibronectin, laminin [9-11], and colla-
gen type I [21], and with BSA as control (50 μg/ml in
Phosphate Buffered Saline (PBS)). After incubation with
IG3 for 5 h at RT, wells were washed and the bottoms
cut off to measure bound radioactivity using a gamma
counter (1480 Wizard 3, Perkinelmer, Waltham, MA,
USA).
Animal model of MI
All procedures followed the recommendations of the Guide
for the Care and Use of Laboratory Animals (Department
of Health and Human Services publication no. NIH 78–23,
1996) and approved by the Icahn School of Medicine at
Mount Sinai Animal Care and Use Committee.
Briefly, male Sprague–Dawley rats (200 to 250 g) under-
went permanent left anterior descending artery ligation
(LAD) (n = 6) as previously described [2,22]. Sham animals
underwent thoracotomy without permanent LAD (n = 6).
Animals were divided into two groups at 2 weeks (n =
3) and 4 weeks (n = 3) post-MI (2 W-MI and 4 W-MI,
respectively), in order to evaluate changes in myocardial
remodeling after MI using IG3 imaging.
Pharmacokinetics and biodistribution studies
After intravenous administration of IG3, blood samples
were collected at different time points (15 min, 30 min,
1 h, 2 h, 3 h, and 4 h). Duplicates of blood samples were
analyzed by gamma counting for radioactivity and TLC
for chemical stability.
We undertook biodistribution and pharmacokinetics
studies for IG3 from John CM et al. [23] and decided to
explant the organs 4 h after injection, washed in PBS,
and collected to analyze radioactivity tissue distribution
by gamma counting.
Cardiac magnetic resonance
To assess ventricular function and myocardial infarct
size, rats underwent cardiac magnetic resonance (CMR)
2 days before nuclear imaging.
Rats were sedated with 1.5% to 2% of isoflurane in oxy-
gen (0.6 l/min). Respiratory rate was monitored using a
magnetic resonance (MR)-compatible monitoring system.
Gd-DTPA (0.6 mmol/Kg, Magnevist®) was injected via tail
vein, as contrast agent, 20 min before full-volume left ven-
tricle and infarct imaging.
A 7 T horizontal bore animal MR scanner (Bruker
BioSpin GmbH, Ettlingen, Germany) was used with a
retrospectively self-gated protocol (IntraGate) as previ-
ously described [2,22]. Briefly, full-volume heart imaging
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ventricle (LV) function and infarct volume measures. Se-
quence parameters were as follows: radiofrequency pulse
(RF): 1 ms sinc pulse (10 lobes, bandwidth: 20 kHz); slab
thickness: 10 mm, 10 mm; FOV: 50 × 50 × (18 to 14) mm3;
Nx ×Ny ×Nz: 128 × 128 × (12 to 9); spatial resolution:
0.312 × 0.312 × 1.5 mm/pixel; TE: 2 ms; TR: 8 ms; number
of repetitions (NR): 50 and flip angle α: 30°; On navigator
slice: RF pulse: 1 ms Gauss pulse (bandwidth: 2.740 kHz);
slice thickness: 5 mm and flip angle αnav: 8°. No more than
70% of all k-lines were used for the reconstruction of 16
cardiac time frames to avoid artifacts from respiratory
movement. Total scan time was approximately 8 to
10 min (Ny ×Nz × TR/NR). The effective number of aver-
ages was approximately 2.5 (70% ×NR/6).
Analysis of global LV function and infarct volume was
calculated using Segment software (Segment v1.9, Medviso,
Sweden). Myocardium segmentation was performed among
at least seven LV short-axis slices outlining both endocar-
dial and epicardial borders in all the cardiac frames. Infarct
area was defined as the bright area on short-axis images
with the largest area of hyperenhancement in both end-
systole and end-diastole frames.
Micro-SPECT/micro-CT imaging with IG3
Radionuclide imaging was performed using a dual-head
micro-single-photon emission computed tomography
(μSPECT) gamma camera with micro-computed tomog-
raphy (μCT) (X-SPECT, Gamma Medica Inc-Siemens,
Northridge, CA, USA). Each animal was injected with ap-
proximately 1 mCi of IG3 (150 μg of protein) via tail vein.
Based on our previous experience and others’ reports
[19,20,24], in vivo heart images were acquired 4 h after
injection under isoflurane anesthesia as described previ-
ously [25]. Subsequently, animals were euthanized by
carbon dioxide asphyxiation and animal myocardium
was explanted for static ex vivo images acquired for
15 min using a low-energy, high-resolution, parallel-hole
collimator. Then, organ samples were weighed and the
percentage of injected dose per gram (%ID/g) of tissue
determined by gamma counting.
Histopathological characterization of myocardial
specimens
Following imaging studies, cardiac specimens where di-
vided into three parts (apex/infarct, MI border and MI
remote tissue), fixed, and embedded in OCT for histo-
pathological studies.
Heart cryosections were used to study myocardial fibro-
sis content using Picrosirius Red Staining (Spectrum
Chemical, New Brunswick, NJ, USA) as previously de-
scribed [26]. Three sections of each sample were stained
and digitally recorded by Zeiss Axioplan2 microscope and
Zeiss AxioVision software (Micro-optik). Total collagencontent was recorded using a bright field light whereas
quality of collagen fibers was further studied using polar-
ized light which allows the qualitative quantification of the
mature, thick fibers as orange and red fibers, and the
newly formed, thin as green and yellow [27]. Collagen de-
position was analyzed by Image J software and presented
as percent of area stained (mean ± SD) for total collagen
content or square micrometer stained (mean ± SD) for the
different types of collagen fibers.
Statistical analysis
Quantitative radiotracer uptake in vitro was calculated
as counts per minute (cpm) bound to immobilized pro-
teins and as percent total injected dose per gram (%ID/g)
for the tissue. To determine statistical significance of
differences in quantitative in vitro data, unpaired t-test
analysis was performed. To test significant difference
among animal groups, one-way analysis of variance
followed by post hoc Bonferroni test for multiple compari-
sons was used. The relation between heart uptake and infarct
size was tested calculating Spearman correlation coefficient.
p values < 0.05 were considered statistically significant.
Results
Radiolabeling of galectin-3
Recombinant human galectin-3 was successfully radiola-
beled with Na123I (Figure 1). The total IG3 eluted be-
tween 1 and 2 ml and the radiochemical yield was > 90%.
The radiochemical purity of IG3 was > 93% as assessed
by radio-TLC. Chemical stability of the tracer in PBS
was analyzed by radio-TLC at 4 h and 24 h after label-
ing. No significant change was observed at these two
time points (90.4% and 90.1% of the main fraction
remained intact 4 h and 24 h after labeling, respectively),
suggesting a good chemical stability.
IG3 in vitro binding assays
Five hours after incubation with IG3 at RT, the bound
radioactivity (cpm bound, mean ± SD) was significantly
higher (p < 0.05) in those wells pre-coated with laminin
(2.45 ± 1.67 cpm), fibronectin (4.72 ± 1.95 cpm), and col-
lagen type I (1.88 ± 0.53 cpm) compared to control, BSA
(0.88 ± 0.31 cpm) as shown in Figure 2. IG3 binding to
ECM components was also observed pre-coating the
wells at lower concentrations (10 μg/ml), showing a sig-
nificant concentration-dependent binding of IG3 to lam-
inin, fibronectin, and collagen type I (data not shown).
IG3 in vivo stability
In vivo metabolic stability of IG3 was assessed using
blood and heart samples 4 h after IG3 injection using
TLC. Unlike the results observed in PBS, 28% and 40%
of the main IG3 fraction remained intact in blood and
Figure 1 IG3 purification on Sephadex G-25 after labeling.
IG3 specific activity (μCi) checked by gamma counting and protein
concentration (μg/ml) quantified by UV spectrophotometry.
Figure 3 IG3 blood uptake at different times after i.v. injection.
After IG3 injection, specific activity of blood samples was gamma
counted. Values are given as %ID/g (mean ± SD) of duplicates
measurements from twelve independent experiments. IG3 uptake
decreased in a time-dependent manner (p for trend < 0.0001). % ID/g,
percent injected dose per gram.
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in vivo degradation of the compound.
IG3 biodistribution and organ uptake
Blood pharmacokinetics of IG3 (Figure 3) showed a
clearance in a time-dependent manner (p for trend <
0.0001); IG3 in blood decreased by 50% 2 h after injec-
tion and by 75% at 4 h.
IG3 biodistribution was examined in all 12 rats. Organ
uptake and heart distribution of IG3 4 h after i.v. admin-
istration are shown in Table 1. Thyroids showed the
highest uptake in the three groups, followed by the kid-
ney, spleen, liver, and lung. However, no significant dif-
ferences were observed in IG3 biodistribution between
groups in the remaining vital organs, muscle, or bone.
IG3 myocardial uptake and imaging
LV ejection fraction (61.3 ± 7.4% vs. 54.0 ± 5.5%) and in-
farct size (16.5 ± 6.4% vs. 12.3 ± 2.2%) measured byFigure 2 IG3 in vitro binding experiments. Solid-phase radiolabeling bin
mean ± SD of duplicates measurements from seven independent experimeCMR was similar in 2 W-MI and 4 W-MI animals,
respectively.
In vivo radionuclide studies using μSPECT showed a
moderate uptake of IG3 in the heart of 2 W-MI rats com-
pared to control and 4 W-MI (Figure 4). Of interest,
ex vivo planar images of the explanted heart confirmed in-
creased uptake of IG3 in MI rats, especially in 2 W-MI
rats compared to control and 4 W-MI rats (Figure 5).
IG3 uptake (%ID/g) in the heart was significantly (p <
0.01) higher in the apex/infarct of 2 W-MI rats (0.15 ±
0.05%) compared to the control animals (0.05 ± 0.04%).
Heart uptake in MI remote (0.10 ± 0.03%) and MI border
(0.11 ± 0.02%) areas of 2 W-MI rats was also significantly
higher than control (0.04 ± 0.03% MI remote and 0.05 ±
0.03% MI border). There was no significant difference IG3
uptake in 4 W-MI rats compared to control and 2 W-MI
rats (Figure 5).ding assays to test IG3 ability to bind to its targets. Values are given as
nts. *p < 0.05 vs. BSA. cmp, counts per minute.
Table 1 Organ biodistribution of IG3
Control 2 W-MI 4 W-MI
MI infarct (apex) 0.058 ± 0.039 0.151 ± 0.047† 0.071 ± 0.059
MI border 0.047 ± 0.028 0.110 ± 0.021* 0.056 ± 0.044
MI remote 0.045 ± 0.033 0.108 ± 0.026* 0.055 ± 0.044
Lung 0.094 ± 0.034 0.194 ± 0.055 0.093 ± 0.073
Liver 0.236 ± 0.249 0.519 ± 0.095 0.192 ± 0.198
Spleen 0.079 ± 0.035 0.356 ± 0.041Φ 0.134 ± 0.118
Kidney 0.502 ± 0.101 0.784 ± 0.149 0.693 ± 0.367
Bone 0.057 ± 0.025 0.070 ± 0.013 0.053 ± 0.034
Thyroid 1.126 ± 1.409 1.326 ± 0.298 1.342 ± 0.223
Muscle 0.015 ± 0.004 0.021 ± 0.001 0.022 ± 0.013
Data are presented as %ID/g (mean ± SD) 4 h after injection.
%ID/g, percent injected dose per gram; MI, myocardial infarction; 2 W-MI,
myocardial infarction 2 weeks old; 4 W-MI, myocardial infarction 4 weeks old.
*p < 0.05 control vs. 2 W-MI rats.
†p < 0.01 control vs. 2 W-MI rats.
Φp = 0.0571 2 W-MI vs. control and 2 W-MI vs. 4 W-MI rats.
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positively correlated with the CMR-verified extent of
scar (%) defined by LGE (rs = 1, p = 0.017).
Collagen deposition in the myocardium
The analysis of collagen deposition by Picrosirius Red
staining showed that the total amount of collagen at 2
and 4 weeks post-MI in the three different areas of the
myocardium was similar (Figure 6a). However, the total
amount of collagen in the infarcted (apical) region wasFigure 4 In vivo μCT, μSPECT, and fusion images in frontal projection
compared to control and 4 W-MI rats by μSPECT. Cardiac localization is con
old; 4 W-MI, myocardial infarction 4 weeks old; μCT, micro-computed tomosignificantly higher at 2 weeks (24.2 ± 5.1%) and 4 weeks
(30.4 ± 7.5%) post-MI compared to control (1.9 ± 1.1%).
No differences of total amount of collagen were ob-
served in the border and remote areas of MI between
control and 2 W-MI animals. Of interest, the total
amount of collagen in those regions was significantly
higher in 4 W-MI animals (MI border: 3.8 ± 2.0% and
MI remote: 1.9 ± 1.2%) compared to control (MI border:
1.9 ± 1.5% and MI remote: 1.1 ± 0.7%).
When we analyzed by Picrosirius polarized light the
quality of collagen fibers in the apex/infarct (Figure 6b),
we found that the amount of mature thick fibers (orange
and red) at 2 and 4 weeks post-MI was significantly higher
than control animals as well as the amount of newly
formed thin fibers (yellow and green). Interestingly,
between 2 and 4 weeks post-MI, the only significant differ-
ence found was that the amount of mature collagen fibers
at 4 weeks post-MI (20.5 ± 11.2 μm2) was higher than at
2 weeks (10.6 ± 5.1 μm2). In the MI border zone, the
quality of collagen fibers was similar in all the groups
(Figure 6b) and in the MI remote area (Figure 6b), the de-
position of thick and thin collagen fibers in the 4 W-MI
rats (2.4 ± 1.9 μm2 thick and 3.6 ± 1.6 μm2 thin) was
higher compared to 2 W-MI rats (1.1 ± 0.7 μm2 thick and
2.4 ± 0.9 μm2 thin).
Discussion
The current study presents a proof of principle that the
radiolabeled IG3 could be employed to target the. Moderate IG3 uptake (white arrows) observed in the heart of 2 W-MI
firmed in the fusion images. 2 W-MI, myocardial infarction 2 weeks
graphy; μSPECT, micro-single-photon emission computed tomography.
Figure 5 IG3 ex vivo heart imaging and uptake. (a) Upper panel: Ex vivo heart imaging 4 h after IG3 administration; Lower panel: In vivo CMR:
four chamber view after Gd-DTPA administration. Scar extension by LGE correlates with IG3 uptake (rs = 1, p = 0.017). CMR, cardiac magnetic
resonance; LA, left atrium; LGE, late gadolinium enhancement; LV, left ventricle; MI, myocardial infarction; μSPECT, micro-single-photon emission
computed tomography; RA, right atrium; RV, right ventricle. (b) Explanted hearts were divided into three parts (apex/infarct, MI border, and MI
remote) for gamma scintillation counting. Values are given as %ID/g (mean ± SD). *p < 0.05 2 W-MI vs. control. †p < 0.01 2 W-MI vs. control. %ID/g,
% injected dose per gram; 2 W-MI, myocardial infarction 2 weeks old; 4 W-MI, myocardial infarction 4 weeks old.
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after an ischemic injury. These preliminary results dem-
onstrate a significant increase of IG3 uptake in the myo-
cardium of 2 W-MI rats compared to control rats.
IG3 biodistribution
After successful labeling and confirming the chemical
stability of the tracer at least for 24 h in PBS by TLC, we
performed solid-phase in vitro binding assays (Figure 2)
that demonstrated that IG3 retained the ability to bind
to certain ECM components [10]. These results sug-
gested that IG3 should be able to successfully bind to
these ECM targets in vivo.
Interestingly, we observed in the animal studies that
only 28% of the IG3 fraction in blood remained intact
4 h after injection suggesting degradation of the com-
pound in vivo. The radioiodination of proteins using
solid-phase oxidative approaches such as the Iodogen
method offers a convenient route to radiolabel probes
that usually affords iodinated histidine and tyrosineresidues. These residues, however, are prone to deiodina-
tion after in vivo administration [28] and generally result
in low label stability and loss of free iodide. Thus, the
high thyroid uptake described points to deiodination of
the tracer as the main metabolic transformation. In
addition to the thyroid, the lungs, liver, and spleen
showed high IG3 uptake suggesting, as described previ-
ously [23], that some organs may accumulate galectin-3
and serve as reservoirs for eventual systemic release or
may participate in IG3 circulation removal. Interestingly,
4 h after injection, the intact IG3 fraction in the myocar-
dium was 40%, significantly higher than that observed in
the blood. This finding suggests that despite the substan-
tial IG3 blood clearance and in vivo degradation, there
seems to be a slight IG3 uptake in cardiac tissue that
may be evidence of specific binding and sufficient for
ex vivo planar imaging. In addition, IG3 heart uptake
was significantly higher at 2 weeks post-MI compared to
the control rats, whereas 4 weeks post-MI the IG3 up-
take was completely resolved. These results agree with
Figure 6 Total collagen deposition and collagen composition in the myocardium. (a) Total collagen deposition in the myocardium. Values
are given as percent of area stained (mean ± SD). *p < 0.05 vs. control, §p < 0.0001 vs. control. (b) Collagen composition in the three heart regions.
MI remote (R), MI border (B), and apical/infarct (A). Values are given as square micrometer stained (mean ± SD). 2 W-MI, myocardial infarction
2 weeks old; 4 W-MI, myocardial infarction 4 weeks old.
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ously described [19]; the decrease over time of fibrosis-
tracer uptake in the infarct region correlated with the re-
duction of newly formed thin collagen fibers (yellow and
green) [27]. Interestingly, this study also described that
even though the total amount of collagen remained simi-
lar over time the thick collagen fibers (orange and red)
increased over time, in agreement with our histological
results (Figure 6b). Yet another study [29], described
three overlapping phases of myocardial remodeling after
injury in rodents: 1) Inflammatory (1 h to 8 h), Prolifera-
tive (48 h to 5 days), and 3) Maturation phase (5 days to
28 days). The peak expression of ECM components in
the scar is during the proliferative phase whereas during
maturation phase most of myofibroblast and endothelial
cells resolve and the formation of a mature scar (com-
prised of dense cross-linked collagen fibers) enhances
myocardial stiffness and thus eventually prompts to dia-
stolic dysfunction and may lead to infarct expansion and
systolic dysfunction.
Given that EMC components’ peak expression is
within the first week after MI and decreases from then
on, we hypothesize that the decrease of IG3 uptake ob-
served 4 weeks after MI is related to a decrease in theamount of thin collagen fibers, myofibroblast, and the
rest of ECM components. In addition, we also observed
4 weeks after MI an increase of the mature and thick
collagen (Figure 6b), suggesting a less IG3 uptake at that
time because of the larger presence of thick collagen fi-
bers that might be preventing the binding of IG3 to col-
lagen molecules and/or any other ECM component.
Although no significant correlation has been observed
between IG3 uptake and collagen content, we do ob-
serve a tendency of a negative correlation between IG3
uptake and thick collagen content and a positive correl-
ation between IG3 uptake and thin collagen content as
much as in the infarct and in the whole heart of MI ani-
mals (data not shown).
Galectin-3 and myocardial remodeling
In the last few years, several studies have focused their at-
tention on the role of galectin-3 in cardiovascular disease,
especially as a reliable biomarker of ECM turnover in HF
patients [12,18,30] that correlated with the adverse out-
come in HF [7,12]. Although never employed in humans,
galectin-3 inhibition in animal studies has resulted in at-
tenuation of cardiac inflammation, fibrosis, and LV dys-
function [5,31]. In these studies, the galectin-3 binding
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and fibroblasts but they are absent from cardiomyocytes
[15]. Inhibition of galectin-3 has also been reported to
result in reduced plaque volume in apolipoprotein-E-
deficient mice [32].
In the present study, 2 days before ex vivo SPECT im-
aging, animals underwent cardiac magnetic resonance
for the assessment of LV function and infarct size by
LGE; all MI animals presented similar ejection fraction
and infarct size. We observed a positive correlation be-
tween IG3 uptake in the apical region and the infarct
size using LGE by CMR.
Molecular imaging of galectin-3
To our knowledge, this is the first attempt to use
galectin-3 for in vivo molecular imaging of the heart. In
another targeting attempt, the role of cardiac galectin-3
in TGRmRen2-27 (Ren-2) rats was studied wherein re-
combinant or biotinylated galectin-3 was pumped into
the rat pericardium over a period of 4 weeks [15] and
galectin-3 was localized to the areas of fibrosis in coloca-
lization with cardiac fibroblast proliferation, collagen
production, and macrophage activation.
Such data and the one here reported support the cred-
ibility of galectin-3 as an imaging tool in myocardial re-
modeling and HF. However, in our case, improvement of
labeling strategies must be done in order to enhance IG3
heart uptake and therefore to get better signal for in vivo
imaging.
Conclusions
The present study reveals the potential of galectin-3 label-
ing to assess the myocardial remodeling process after MI.
However, since IG3 heart uptake was not substantial
enough for in vivo imaging at this stage and although IG3
appears to be an attractive targeting agent, signal enhan-
cing strategies need to be developed if this agent wants to
be translated into a clinically useful imaging agent.
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